Venture-backed Zymeworks tops up IPO raise to $86 mln
Zymeworks Inc (NYSE, TSX: ZYME) has raised additional proceeds from its initial public offering in Canada and the United States with the partial exercise of the over-allotment option. In total, the Vancouver biotherapeutics provider secured about $86 million (US$63.6 million). Zymeworks earlier said the proceeds will be used to further advance the company’s pipeline of product candidates and increase liquidity. Launched in 2003, Zymeworks is backed by multiple venture capital and strategic investors, including BDC Capital, Celgene, CTI Life Sciences Fund, Eli Lilly & Co and Lumira Capital.
31 May 2017•3 mins read
